In this context, we advocate for a pragmatic approach to select the most suitable partnering incretin, possibly a dual GLP-1R/GIPR agonist such as NNCOO90-2746 (Frias et al., 2017), to achieve the appropriate therapeutic outcome for the long-term management of metabolic diseases like T2D and obesity. This evidence concerns the gene GIPR and Obesity.